The Vector State Scientific Center for Virology and Biotechnology reported that 98% of volunteers vaccinated three times with the EpiVacCoron-N vaccine retained antibodies for six months, RIA Novosti reports.

It is clarified that the same period of time antibodies persisted in 81% of the subjects who underwent a double vaccination with the drug.

The center emphasized that the drug does not cause allergic reactions and does not lead to changes in the respiratory system, which is especially important for older people suffering from diseases of the bronchopulmonary system. Clinical trials of the vaccine indicate that it has a high level of safety, the manufacturer said.

A day earlier, the Ministry of Health authorized trials of the EpiVacCoron-N vaccine on people over 60 years of age. The research will take place before the end of this year, 300 volunteers will take part in it.

EpiVacCorona became the second coronavirus vaccine registered in Russia, and the EpiVacCorona-N vaccine was developed on its basis. The first vaccine against COVID-19 in Russia and the world was developed by the Gamaleya National Research Center for Epidemiology and Microbiology together with the Russian Direct Investment Fund, the drug was called Sputnik V. Subsequently, the vaccines CoviVac, Sputnik Light and Sputnik M were registered.

bbabo.Net